News in brief: Cost blowout with rising immunoglobulin use; First treatment in two decades to improve PFS  in DLBCL; Vitamin K in diet may reduce atherosclerotic cardiovascular disease 

Cost blowout for rising immunoglobulin use in SHG Public funding should be continued for immunoglobulin (Ig) therapy for the treatment of secondary hypogammaglobulinaemia (SHG), the Medical Services Advisory Committee has recommended, after conducting a post market review. However MSAC expressed concern that there was with very little evidence to support increasing use of Ig use ...

Already a member?

Login to keep reading.

© 2021 the limbic